kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human B7-2 / CD86 Protein, His tag (MALS verified), 100µg  

Recombinant Human B7-2 / CD86 Protein, His tag (MALS verified), 100µg

Recombinant Human B7-2 / CD86 (Leu 26 - Pro 247), expressed from human 293 cells (HEK2cells), His tag (MALS verified)

Recombinant human protein, CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

More details


Availability: within 7 days

364,00 €

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Recombinant Human B7-2, His Tag (CD6-H5223) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
Predicted N-terminus: Leu 26

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.2 kDa. The protein migrates as 45-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy"
Liu, Wang, Du et al
Sci Transl Med (2023) 15 (685), eabm5663
(2) "In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy"
Hajihassan, Afsharian, Ansari-Pour
J Immunol Methods (2023) 513, 113425
(3) "CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis"
Ma, Kamle, Akosman et al
Front Immunol (2022) 13, 1056397
Showing 1-3 of 4765 papers.